(secondQuint)Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia.

 OBJECTIVES: I.

 Determine the response rate in asymptomatic patients with stage 0, I, or II B-cell chronic lymphocytic leukemia treated with theophylline.

 II.

 Determine the toxicity of this treatment in these patients.

 OUTLINE: Patients receive oral theophylline daily.

 Daily treatment continues for a maximum of 6 months in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 4 months for 1 year.

 PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study over approximately 10 months.

.

 Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of theophylline in treating patients who have in situ, stage I, or stage II chronic lymphocytic leukemia.

